References
1. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer . 2005;45(3):256-264.
2. Büttgen K, Levy M. Juvenile Xanthogranuloma (JXG). In: Corona R ed. UpToDate ®. Waltham, MA: UpToDate, Wolters Kluwer; 2021.
3. Rajendra B, Duncan A, Parslew R, Pizer BL. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine.Pediatr Blood Cancer . 2009;52(3):413-415.
4. Maintz L, Wenzel J, Irnich M, Reinhard H, Bieber T. Successful treatment of systemic juvenile xanthogranulomatosis with cytarabine and 2-chlorodeoxyadenosine: case report and review of the literature.Br J Dermatol . 2017;176(2):481-487.
5. Histiocyte_Society, Histiocytosis NACf, Minkov M. ClinicalTrials.gov Identifier: NCT02205762: LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis. ClinicalTrialsgov. Vol. 2022 U.S. National Library of Medicine: National Institutes of Health; 2014.
6. Xu J, Huang X, Wen Y, et al. Systemic Juvenile Xanthogranuloma has a Higher Frequency of ALK Translocations than BRAFV600E Mutations. J Am Acad Dermatol . 2020.
7. Diamond EL, Durham BH, Haroche J, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discov . 2016;6(2):154-165.
8. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol . 2019;37(31):2857-2865.
9. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.Cell . 2010;140(2):209-221.
10. Yao Z, Yaeger R, Rodrik-Outmezguine VS, et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.Nature . 2017;548(7666):234-238.
11. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.N Engl J Med . 2012;366(3):207-215.
12. Lin Q, Zhang H, Ding H, et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J Transl Med . 2019;17(1):298.
13. Sahin IH, Klostergaard J. BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues.JCO Oncol Pract . 2021;17(12):723-730.
14. Dankner M. Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. JCO Precis Oncol . 2018;2:1-12.
15. Lokhandwala PM, Tseng LH, Rodriguez E, et al. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. BMC Cancer . 2019;19(1):665.